This study compared rates of spontaneous hepatitis B e antigen (HBeAg) -positive to -negative seroconversion in chronic carriers of hepatitis B virus (HBV) with rates reported during interferona therapy. Four hundred fifty-four Asian-American HBeAg-positive HBV carriers, followed for 1 -10 years, were tested approximately every 6 months for HBeAg. Patients with alanine aminotransferase levels §50 IU/mL at entry had 1067.3 seroconversions/10 5 person-months in the 5 -to 19-year age group, 1753.3 in the 20 -to 34-year group, and 1257.2 in the 35 -to 50-year group. Published data indicate that 30% of children and 33% of adults seroconvert during interferon-a treatment and follow-up. In our study population, spontaneous seroconversion occurred in 15% of children (95% confidence interval [CI], 8% -27%), 23% of adults 20 -34 years (95% CI, 15% -34%), and 17% of adults 35 -50 years (95% CI, 10% -28%) during the same interval. The high rate of spontaneous seroconversion should be weighed in decisions to treat HBV carriers with interferon-a.
Chronic hepatitis B virus (HBV) infection exhibits a wide
crease the probability of seroconversion to HBeAg-negative. Nonetheless, treatment with interferon-a is ineffective for onespectrum of clinical manifestations, from a completely asymptomatic condition detectable only by the long-term presence of half to two-thirds of patients. In a metaanalysis of published clinical trials, Wong et al. [5] estimated that 33% of treated serum hepatitis B surface antigen (HBsAg) to severe liver disease resulting in cirrhosis or hepatocellular carcinoma (HCC) subjects seroconverted to HBeAg-negative compared with 12% of untreated controls during follow-up periods of 12 -18 [1] . Among chronically infected persons, the presence of serum hepatitis B e antigen (HBeAg) indicates active viral replication, months. Treatment of healthy HBeAg-positive carriers is not recommended [6, 7] , and even among HBeAg-positive patients higher infectivity, and the potential for more liver damage [1, 2] . HBeAg appears early in the course of infection and often eligible for treatment, it is those with the highest elevations of alanine aminotransferase (ALT) level or histologic evidence of persists in chronic infection. Development of antibody to HBeAg (anti-HBe) usually follows seroconversion from liver damage that are most likely to respond [6, 8] . The information provided by this study may be useful to clinicians counHBeAg-positive to HBeAg-negative.
The aim of the present study was to estimate the spontaneous seling patients with HBeAg-positive hepatitis. HBeAg-positive to -negative seroconversion rate in a population of Asian-American HBV carriers identified through comMethods munity screening and to assess the benefit these patients might derive from interferon-a therapy. Long-term prospective studStudy population. Since 1985, the Liver Cancer Prevention ies of the natural history of the HBeAg-positive carrier state Center at Fox Chase Cancer Center has followed 1522 Asianare rare [3] . Much of what is known about the natural course American HBV carriers by use of serologic tests for viral and of HBeAg-positive hepatitis has been derived from studies of biochemical markers of liver disease. The population includes both patients in the tertiary care setting who presented with a liverimmigrants and persons born in the United States. Nearly all parelated complaint. Among chronic carriers identified incidentients were initially identified as HBsAg-positive through screening tally (as in blood donation), the prevalence of HBeAg is usually campaigns in ethnic Asian communities in the Philadelphia area and were requested to return for serologic tests either every 6 low [4] . was the early detection of HCC [9] .
All subjects gave informed consent to participate, and the protocol was For this analysis, subjects aged 5-50 years who were HBeAgapproved by the Fox Chase Cancer Center Institutional Review Board.
positive at least once during a minimum of 6 months of follow- hundred fifty-four patients met these criteria. The median follow-JID 1997;176 (October) samples per subject was 4 (range, 2-34). One subject was known prior to seroconversion. At their latest tests, the 4 subjects who were HBV DNA-negative prior to seroconversion remained HBV DNA-negative. Thirty-nine (72.2%) of the 54 patients Results who were HBV DNA-positive before seroconversion have experienced occasional brief reversions to HBV DNA-positive Four hundred fifty-four HBeAg-positive HBV carriers were followed for 17,787 person-months. Characteristics at study during follow-up after becoming HBV DNA-negative. At last follow-up, 49 (84.5%) of the 58 patients were HBV DNAentry are summarized in table 1. Country of birth was recorded for 342 subjects (75.3%). Of these, 326 (95.3%) were born negative. Two subjects among those who had stable seroconversions became HBsAg-negative after HBeAg seroconveroutside the United States. Of 435 tested for HBV DNA at study entry, 420 (96.6%) were positive. The serum ALT level was sion, 1 at 5 years later and the other at 9 years later.
/ 9d35$$oc36 08-06-97 12:49:32 jinfa UC: J Infect Thirty-nine (67.2%) of 58 persons who stably seroconverted was no significant difference in the incidence of stable seroconversion between female and male carriers (relative risk [RR] Å 0.88; had elevated ALT levels at least once before seroconversion, and 15 (25.7%) had levels ú2.5 times the upper limit of normal. 95% confidence interval [CI], 0.50-1.6) controlling for ALT status. Subjects who had an elevated ALT level at study entry were Fifty-two (89.7%) of 58 subjects had normal ALT levels by the second visit following seroconversion.
significantly more likely to seroconvert during follow-up ([RR Å 3.3; 95% CI, 1.9-5.8] controlling for gender). Figure 2 shows the product-limit estimates of the proportion of subjects who stably seroconverted to HBeAg-negative by age.
The incidence rates of stable seroconversion per personmonth were estimated by age group and initial ALT status. The analysis shows that among subjects HBeAg-positive at age 5, 25% had a stable seroconversion by age 17, 50% by age 24, Subjects included in this analysis were those with stable seroconversions or at least 1 year of follow-up from study entry and 75% by age 33. At age 50, 8% remained HBeAg-positive. After age 50, seroconversions were rare (data not shown). There or both (n Å 338). This restriction was made because a mini- in seroconversion rates with age in the normal versus elevated ALT groups. Table 2 shows the estimated incidence rates. had an elevated ALT level at any time prior to seroconversion (n Å 118). Person-time was included from the time of the first elevated ALT level rather than from study entry. There were 39 stable seroconversions in 2812 person-months of observaperiod was 10% -16%. Because spontaneous seroconversion is tion. The last column of table 2 shows the estimated incidence an ongoing process, we also estimated the additional time (ú15 rates of stable seroconversion for this model. months) necessary for spontaneous seroconversions to equal In order to provide incidence rates of seroconversion among the probability of seroconversion reported for interferon-a therpatients as comparable as possible to those meeting eligibility apy. These differences ranged from 8 to 18 months of additional criteria for most interferon clinical trials, we also calculated time needed to achieve an equal probability of seroconversion. the rates by age group for subjects with elevated ALT level who were HBeAg-positive for at least 6 months and 2 consecuDiscussion tive blood samples. There were 25 stable seroconversions in 2266 person-months of observation in this group. The incidence Interferon-a is the only drug currently approved for the treatment of chronic HBV infection. For treated patients who serorates per 100,000 person-months were 1071.6 (95% CI, 481.7 -2384.2) for the 5 -19 year age group, 1301.8 (95% CI, 700.5 -convert to HBeAg-negative, long-term prognosis appears to be good [16, 17] . Most patients treated with interferon-a, how-2419.4) for the 20 -34 year age group, and 958.6 (95% CI, 498.8 -1842.3) for the 35 -50 year group. ever, do not seroconvert. The long-term effects of treatment on nonresponders are more difficult to assess because few studComparison with interferon-a therapy. Table 3 shows the comparison of spontaneous versus interferon-a seroconversion ies of nonresponders have been published [18] . Because treatment is associated with a variety of adverse effects, including rates for patients with elevated ALT levels. We estimated the cumulative incidence of seroconversion within 15 months for flu-like syndrome, fatigue, headache, leukopenia, and psychiatric disturbances, [6, 17, 19] , patients considering treatment each age group in the untreated study patients versus response percentages published from randomized clinical trials. The seneed to be informed of both the probability of nonresponse and of seroconversion without treatment. Estimates of the latter roconversion rate predicted for interferon-a therapy was modestly higher in each age group, and the difference from the number have not been readily available.
In this study, we estimated spontaneous HBeAg-negative probability of spontaneous seroconversion in the same time seroconversion rates in HBV carriers of different ages in order to provide information useful in deciding whether to treat with [5] . The rates of spontaneous HBeAg-negative seroconversion observed in our study are similar to those restable seroconversion for children with normal ALT levels was low (Ç2%/year), in adults it occurred at Ç5% -8%/year. Seroported for both Asian and non-Asian HBV carriers in other studies [3, 4, 22, 23, 25] . conversions occurred even more frequently in those with elevated ALT levels at study entry: Ç11%/year for children and
In our study, we have estimated the proportion of HBV carriers who will become HBeAg-negative before the age of 10% -19%/year for adults. We estimated the potential efficacy of interferon-a therapy in the HBeAg-positive carrier popula-50. The clinical trials of interferon-a have estimated the proportion of HBeAg-positive carriers who will respond to treatment. tion with elevated ALT levels by comparing expected rates of spontaneous seroconversion with the published response rates What still remains unknown is whether the responders to interferon-a and those who will seroconvert spontaneously reprefrom clinical trials. The comparison between spontaneous and interferon-a -induced seroconversion rates can be expressed sent the same subpopulation of HBV carriers. Carefully designed long-term epidemiologic studies of nonresponders to by two quantitative measures: the cumulative incidence of seroconversion expected during a fixed period and the number of interferon-a therapy would be of great value in answering this essential question. months required to achieve a given probability of seroconversion (table 3) .
The rather modest improvements of interferon-a therapy of spontaneous seroconversion by even a few months through treatment may have substantial benefit [17] . For healthier carriers, however, treatment is not only unlikely to be effective, but Appendix its use in an early stage of the disease may also decrease response to later therapy because repeated courses have not
Since the time variable of interest was age rather than time on study and ages of entry into the study varied, the survival been shown to be effective in nonresponders [20, 21] .
What is unknown is whether interferon-a merely accelerates analysis used left truncation and right censoring [10] . Time of infection was unknown for all subjects, but it was assumed the natural process of seroconversion by a few months in those who would have seroconverted spontaneously or whether some that it occurred in infancy or early childhood, as is usual in populations in which HBV is endemic [26] . The age-specific of the patients who respond to therapy might never seroconvert otherwise. In our relatively healthy study population, 8% reincidence rates in table 2 were calculated using Poisson regression. In addition, we calculated the incidence rates nonparametmained positive at age 50. No known indicators can predict which carriers will spontaneously seroconvert before the advent rically using a kernel smoother for the hazard curve [11] . The results were similar to those produced by Poisson regression. of serious liver disease and which are likely to remain HBeAgpositive throughout life. Until more becomes known about the Two measures were used to compare the observed incidence rates of seroconversion to those expected from interferon-a effect of therapy on the natural history of chronic infection in both responders and nonresponders, a conservative approach therapy. The first was the cumulative incidence of seroconversion over a given time period. When the incidence rate (l) of to the use of interferon-a is appropriate. Of particular importance is the evaluation of the status of the patient's underlying seroconversion is constant, the cumulative incidence (CI in formula) in a time interval (t) is estimated as CI t Å 1 0e 0lDt . liver disease over a long period prior to the recommendation for therapy. Many patients have transient elevations of ALT The cumulative incidence can be interpreted as the average probability (p) for an individual of seroconverting within the level in the period immediately prior to spontaneous seroconversion [22, 23] .
interval t [27] . To estimate the additional time (T) required to achieve a probability of seroconversion equal to that of interOur study population was composed of Asian-Americans. It has been reported that interferon-a therapy is less effective for feron-a therapy, we solve for t and subtract the median number of months (m) required for treatment and follow-up in the Chinese patients and for patients who acquired infection early in life [8] . This association may, however, be artifactual since interferon-a clinical trials: T Å 0[ln(1 0 p)/l] 0 m. The validity of our method of estimation depends upon two the three major randomized clinical trials of interferon-a involving Chinese patients have included HBV carriers with norassumptions. First, there should be no secular trend in the age-specific incidence rates during the time interval t. Second, mal ALT levels. Most other randomized trials have included only patients with elevated ALT levels, a predictor of better competing risks must be small. Time intervals of interest were relatively short in this case, and it is unlikely that either a response [6] . Lok et al. [24] found that 33% of Chinese subjects with elevated pretreatment ALT levels responded, a proportion secular trend or competing risks significantly affected the results. equal to that of the other studies reviewed for the metaanalysis
